The bill outlines the authority granted to MassHealth to negotiate directly with drug manufacturers for supplemental rebate agreements, as established in July 2019. This authority has significantly expedited the process of entering into these agreements, resulting in active contracts with 32 manufacturers that yield approximately $584 million in annual savings. The bill highlights the introduction of value-based payment (VBP) agreements, which link rebate amounts to clinical outcomes and efficacy data, allowing MassHealth to recoup payments if a drug proves ineffective or requires extended therapy.

Additionally, the bill includes a comprehensive list of drug manufacturers and the specific drugs covered under these negotiated agreements, with several new entries for 2024 and beyond. Notably, the language inserted into the bill specifies the names of drugs and their initial years of contract, enhancing transparency regarding the agreements in place. The bill emphasizes the ongoing collaboration between MassHealth and pharmaceutical companies to ensure accountability for drug efficacy and financial responsibility for clinical outcomes.